Shares of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) received an average recommendation of “Hold” from the fifteen brokerages that currently cover the business, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating on the company. The 12-month average price target among analysts who have rated the stock over the past year is $51.63.
A number of stock analysts have recently commented on the company. Credit Suisse Group lowered its price target on Fresenius Medical Care AG & Co. KGaA from €66.00 ($70.97) to €61.00 ($65.59) in a Tuesday, March 1 research note . StockNews.com began covering Fresenius Medical Care AG & Co. KGaA in a Tuesday, May 10 report. They set a “buy” rating on the stock. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($52.37) to €51.00 ($54.84) and assigned the stock a “underweight” rating in a Thursday, May 5, report. Oddo Bhf upgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperforming” rating and set a target price of €72.00 ($77.42) on the stock in a report of research from Tuesday, March 1. Finally, Berenberg Bank lowered its price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($91.29) to €83.40 ($89.68) in a Thursday, March 17 research report. .
FMS stock opened at $28.69 on Friday. The stock has a market capitalization of $16.81 billion, a P/E ratio of 16.39, a P/E/G ratio of 1.18 and a beta of 1.17. The company has a debt ratio of 0.51, a current ratio of 1.26 and a quick ratio of 0.93. Fresenius Medical Care AG & Co. KGaA has a 1 year minimum of $27.92 and a 1 year maximum of $42.45. The company has a fifty-day moving average price of $31.75 and a 200-day moving average price of $32.09.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly results on Wednesday, May 4. The company reported EPS of $0.38 for the quarter, beating analysts’ consensus estimate of $0.30 by $0.08. The company posted revenue of $5.10 billion in the quarter, compared to $4.97 billion expected by analysts. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. As a group, analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 1.99 for the current year.
The company also recently announced an annual dividend, which was paid on Friday, May 27. Investors of record on Monday, May 16 received a dividend of $0.7093. This represents a return of 3.4%. The ex-dividend date was Friday, May 13. The dividend payout ratio (DPR) of Fresenius Medical Care AG & Co. KGaA is currently 28.00%.
A number of hedge funds and other institutional investors have recently increased or reduced their holdings in FMS. First Trust Advisors LP increased its position in Fresenius Medical Care AG & Co. KGaA by 12.5% in the first quarter. First Trust Advisors LP now owns 86,559 shares of the company valued at $3,508,000 after purchasing an additional 9,624 shares during the period. Citadel Advisors LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 8.2% during the second quarter. Citadel Advisors LLC now owns 20,662 shares of the company worth $859,000 after acquiring 1,558 additional shares in the last quarter. Millennium Management LLC acquired a new equity position in Fresenius Medical Care AG & Co. KGaA in Q2 worth $266,000. Advisor Group Holdings Inc. increased its equity stake in Fresenius Medical Care AG & Co. KGaA by 6.9% in Q3. Advisor Group Holdings Inc. now owns 10,346 shares of the company valued at $362,000 after purchasing an additional 664 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA shares by 3.9% during the 3rd quarter. American Century Companies Inc. now owns 8,239 shares of the company valued at $288,000 after acquiring 307 additional shares in the last quarter. Institutional investors hold 4.73% of the company’s shares.
About Fresenius Medical Care AG & Co. KGaA (Get a rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here